발간시클로비르(Valganciclovir) 시장 규모, 점유율, 성장 분석 : 제품 유형별, 적응증별, 용도별, 환자 유형별, 최종사용자별, 유통 채널별, 지역별 - 산업 예측(2026-2033년)

Global Valganciclovir Market size was valued at USD 232.5 Billion in 2024 and is poised to grow from USD 245.99 Billion in 2025 to USD 386.18 Billion by 2033, growing at a CAGR of 5.8% during the forecast period (2026-2033).

The global valganciclovir market is primarily influenced by the increasing number of immunocompromised patients, particularly those receiving solid organ and hematopoietic stem cell transplants, who require effective cytomegalovirus (CMV) prophylaxis and treatment. Valganciclovir, an oral prodrug, has revolutionized CMV management by facilitating outpatient therapy and replacing lengthy intravenous treatments, thereby minimizing graft loss and healthcare costs associated with CMV morbidity. The market has also become more competitive with the introduction of generics following patent expirations, enhancing access in both developed and emerging markets. Factors driving growth include rising transplant volumes, an aging population, and the adoption of CMV DNA monitoring for preemptive therapy, all of which encourage oral valganciclovir use due to its cost-effectiveness and reduced hospital stays.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Valganciclovir market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Valganciclovir Market Segments Analysis

Global valganciclovir market is segmented by product type, indication, application, patient type, end user, distribution channel and region. Based on product type, the market is segmented into Oral Formulations and Injectable Formulations. Based on indication, the market is segmented into Cytomegalovirus (CMV) Retinitis, Cytomegalovirus (CMV) Infection (Post-transplant prophylaxis) and Congenital CMV Infection. Based on application, the market is segmented into Cytomegalovirus Treatment and Transplantation Prophylaxis. Based on patient type, the market is segmented into Pediatric Patients, Adult Patients and Geriatric Patients. Based on end user, the market is segmented into Hospitals, Clinics and Homecare Settings. Based on distribution channel, the market is segmented into Online Pharmacies, Retail Pharmacies and Hospital Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Valganciclovir Market

The growth of the global valganciclovir market has been significantly influenced by several key factors. Enhanced access programs, increased clinician awareness, and the deeper integration of valganciclovir into treatment protocols have made it possible for a larger number of patients to receive necessary therapy. Initiatives aimed at supporting patients and improved distribution networks have lowered barriers to treatment initiation. Furthermore, clearer clinical guidelines and rising familiarity among prescribers promote the timely and consistent use of the medication. This increased adoption transforms eligible patients into treated individuals, thereby driving ongoing demand and encouraging healthcare providers to adopt valganciclovir as a standard therapy for specific viral infections, facilitating consistent market growth.

Restraints in the Global Valganciclovir Market

Concerns regarding the safety profile of valganciclovir, particularly its potential for causing hematologic suppression and renal complications, impact clinicians' readiness to prescribe it unless the therapeutic advantages significantly surpass the associated risks. This cautious approach limits the number of patients deemed appropriate for treatment. Additionally, the requirement for ongoing laboratory monitoring and the management of potential adverse effects adds complexity and resource demands, which may deter practitioners in environments with insufficient support. As a result, these considerations lead to conservative prescribing habits, often favoring alternative therapies in borderline situations, hindering wider acceptance despite the existing medical necessity.

Market Trends of the Global Valganciclovir Market

The Global Valganciclovir market is witnessing a significant trend toward increased accessibility, reshaping treatment dynamics and enhancing patient outcomes across various healthcare settings. This expansion is fueled by strengthened partnerships within the supply chain, enhanced regulatory frameworks, and strategic payer engagement, allowing for wider distribution of the drug beyond traditional tertiary medical centers. Collaborations between manufacturers and public health organizations are focused on improving affordability and patient assistance programs. Additionally, the rise of telemedicine and decentralized care models is enabling easier prescribing and monitoring in underserved populations. This accessibility push not only fosters earlier interventions and better patient adherence but also creates reliable demand patterns, prompting strategic investments in production capacity and outreach efforts.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Patent Analysis

Global Valganciclovir Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Oral Formulations
• Injectable Formulations

Global Valganciclovir Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Cytomegalovirus (CMV) Retinitis
• Cytomegalovirus (CMV) Infection (Post-transplant prophylaxis)
• Congenital CMV Infection

Global Valganciclovir Market Size by Application & CAGR (2026-2033)

• Market Overview
• Cytomegalovirus Treatment
• Transplantation Prophylaxis

Global Valganciclovir Market Size by Patient Type & CAGR (2026-2033)

• Market Overview
• Pediatric Patients
• Adult Patients
• Geriatric Patients

Global Valganciclovir Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Homecare Settings

Global Valganciclovir Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies

Global Valganciclovir Market Size & CAGR (2026-2033)

• North America (Product Type, Indication, Application, Patient Type, End User, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Indication, Application, Patient Type, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Indication, Application, Patient Type, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Indication, Application, Patient Type, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Indication, Application, Patient Type, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hetero Labs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ViiV Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations